Eiger Biopharmaceuticals (NASDAQ:EIGR) Earns “Buy” Rating from LADENBURG THALM/SH SH

Share on StockTwits

LADENBURG THALM/SH SH restated their buy rating on shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) in a report released on Monday, AnalystRatings.com reports. They currently have a $28.00 price objective on the biotechnology company’s stock.

“We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs.”,” the firm’s analyst commented.

Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Eiger Biopharmaceuticals from a buy rating to a hold rating in a research note on Thursday, August 8th. ValuEngine upgraded Eiger Biopharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, July 2nd. KeyCorp began coverage on Eiger Biopharmaceuticals in a research note on Wednesday, June 26th. They set an overweight rating and a $10.72 price target on the stock. Citigroup began coverage on Eiger Biopharmaceuticals in a research note on Wednesday, June 26th. They set a buy rating and a $22.00 price target on the stock. Finally, Wedbush restated an outperform rating and set a $35.00 price target on shares of Eiger Biopharmaceuticals in a research note on Tuesday, June 18th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Eiger Biopharmaceuticals currently has an average rating of Buy and a consensus price target of $28.34.

NASDAQ EIGR opened at $9.77 on Monday. Eiger Biopharmaceuticals has a twelve month low of $8.40 and a twelve month high of $15.33. The company has a debt-to-equity ratio of 0.36, a current ratio of 9.64 and a quick ratio of 8.16. The stock has a 50-day simple moving average of $10.71 and a 200 day simple moving average of $11.96.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02). As a group, analysts predict that Eiger Biopharmaceuticals will post -2.49 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can bought a new stake in shares of Eiger Biopharmaceuticals in the 2nd quarter valued at approximately $28,000. Tower Research Capital LLC TRC grew its stake in shares of Eiger Biopharmaceuticals by 1,719.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,626 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Eiger Biopharmaceuticals in the 2nd quarter valued at approximately $113,000. Jane Street Group LLC bought a new stake in shares of Eiger Biopharmaceuticals in the 4th quarter valued at approximately $114,000. Finally, Wedbush Securities Inc. bought a new stake in shares of Eiger Biopharmaceuticals in the 1st quarter valued at approximately $179,000. Hedge funds and other institutional investors own 80.68% of the company’s stock.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Story: How can investors find ex-dividend dates?

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mirum Pharmaceuticals  Research Coverage Started at Raymond James
Mirum Pharmaceuticals Research Coverage Started at Raymond James
i3 Verticals  PT Raised to $28.00
i3 Verticals PT Raised to $28.00
PTC Therapeutics’  Hold Rating Reaffirmed at Barclays
PTC Therapeutics’ Hold Rating Reaffirmed at Barclays
Halozyme Therapeutics  Receives “Sell” Rating from Barclays
Halozyme Therapeutics Receives “Sell” Rating from Barclays
Eiger Biopharmaceuticals  Earns “Buy” Rating from LADENBURG THALM/SH SH
Eiger Biopharmaceuticals Earns “Buy” Rating from LADENBURG THALM/SH SH
Intec Pharma  Earns Hold Rating from LADENBURG THALM/SH SH
Intec Pharma Earns Hold Rating from LADENBURG THALM/SH SH


© 2006-2019 Ticker Report